



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/800,917	03/16/2004	Gertrud Hotten	2923-609	2179
6449 7590 04/18/2007 ROTHWELL, FIGG, ERNST & MANBECK, P.C. 1425 K STREET, N.W. SUITE 800 WASHINGTON, DC 20005			EXAMINER ROMEO, DAVID S	
			ART UNIT 1647	PAPER NUMBER

SHORTENED STATUTORY PERIOD OF RESPONSE	NOTIFICATION DATE	DELIVERY MODE
30 DAYS	04/18/2007	ELECTRONIC

**Please find below and/or attached an Office communication concerning this application or proceeding.**

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Notice of this Office communication was sent electronically on the above-indicated "Notification Date" and has a shortened statutory period for reply of 30 DAYS from 04/18/2007.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PTO-PAT-Email@rfem.com



## UNITED STATES DEPARTMENT OF COMMERCE

## U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

10/800,917

EXAMINER
----------

ART UNIT	PAPER
----------	-------

20070321

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

## Commissioner for Patents

The reply filed on 01/09/2007 is not fully responsive to the prior Office Action because of the following omission(s) or matter(s): Applicants elected the species angiogenesis. However, Applicants were required under 35 U.S.C. 121 to elect a single disclosed species from among the following patentably distinct species: treatment of osteoporosis, arthrosis, skin, mucous membranes, epithelium, or teeth. Claims 6-7 and 10-15 were generic. Angiogenesis is generic to the treatment of osteoporosis, arthrosis, skin, mucous membranes, epithelium, or teeth. Applicants acknowledge that claims 6-7, 10-11 and 14-15 encompass angiogenesis. The treatment of bone is generic to osteoporosis. The treatment of cartilage is generic to arthrosis. See 37 CFR 1.111. Since the above-mentioned reply appears to be *bona fide*, applicant is given **ONE (1) MONTH or THIRTY (30) DAYS** from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

David S Romeo  
Primary Examiner  
Art Unit: 1647